Lasa SupergenericsNSE:LASA +1.61%44 Current Ratio is 0.62 as of Mar. 2026, which is 39% below its 10-year median of 1.01. GuruFocus rates NSE:LASA with a GF Score™ of 44/100 and a GF Value™ of ₹4.34 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 996 Drug Manufacturers companies, Lasa Supergenerics ranks worse than 92.07% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lasa Supergenerics's current ratio for the quarter that ended in Mar. 2026 was 0.62.
Lasa Supergenerics has a current ratio of 0.62. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Lasa Supergenerics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Lasa Supergenerics's Current Ratio or its related term are showing as below:
NSE:LASA'
s Current Ratio Range Over the Past 10 Years
Min: 0.62 Med: 1.01 Max: 1.9
Current: 0.62
During the past 11 years, Lasa Supergenerics's highest Current Ratio was 1.90. The lowest was 0.62. And the median was 1.01.
NSE:LASA's Current Ratio is ranked worse than 92.07% of 996
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:LASA: 0.62
Lasa Supergenerics (NSE:LASA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lasa Supergenerics Current Ratio Related Terms
Lasa Supergenerics Current Ratio Historical Data
* Premium members only.
The historical data trend for Lasa Supergenerics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lasa Supergenerics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lasa Supergenerics Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lasa Supergenerics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lasa Supergenerics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lasa Supergenerics (NSE:LASA) has a Current Ratio of 0.62 as of Mar. 2026. This is 39% below median its historical median of 1.01. Over the past decade, Lasa Supergenerics' Current Ratio has ranged from 0.62 to 1.90. According to the industry distribution chart, Lasa Supergenerics ranks #917 out of 996 companies in the Drug Manufacturers industry, placing it in the top 92.1%.
Is Lasa Supergenerics' Current Ratio too high?
Lasa Supergenerics' current Current Ratio of 0.62 is 39% below median its 10-year median of 1.01. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 1.90. The Drug Manufacturers industry median Current Ratio is 2.00. Lasa Supergenerics' value of 0.62 is 69% below this industry median. Based on the distribution chart, Lasa Supergenerics ranks #917 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lasa Supergenerics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lasa Supergenerics' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lasa Supergenerics ranks #917 out of 996 companies for Current Ratio. This places Lasa Supergenerics in the lower half of its industry. The industry median Current Ratio is 2.00. Lasa Supergenerics' value of 0.62 is 69% below this benchmark. Historically, Lasa Supergenerics' own Current Ratio has ranged from 0.62 to 1.90 over the past decade. While the company's 10-year median is 1.01 vs. the industry median of 2.00, Lasa Supergenerics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lasa Supergenerics's current Current Ratio of 0.62 is 69% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lasa Supergenerics's current Current Ratio is 0.62, which is 39% below median its own 10-year median of 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lasa Supergenerics stock overvalued right now?
Based on GuruFocus' analysis, Lasa Supergenerics (NSE:LASA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹4.34, compared to a current price of ₹7.50 — trading 72.8% above its estimated fair value. The current Current Ratio is 0.62, which is 39% below median its 10-year median of 1.01 and 69% below the Drug Manufacturers industry median of 2.00. Lasa Supergenerics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lasa Supergenerics (NSE:LASA), the current Current Ratio is 0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lasa Supergenerics (NSE:LASA) Overvalued in 2026?
Based on GuruFocus' analysis, Lasa Supergenerics stock appears to be overvalued.
The current stock price of ₹7.50 is trading 72.8% above its estimated GF Value™ of ₹4.34.
GuruFocus considers Lasa Supergenerics to be Significantly Overvalued.
Key valuation signals for NSE:LASA:
Current Ratio: 0.62 (39% below median its 10-year median of 1.01)
GF Value™: ₹4.34 vs. price of ₹7.50 (72.8% above fair value)
Industry Position: 69% below the Drug Manufacturers median (#917 of 996)
No single metric tells the full story. See the NSE:LASA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lasa Supergenerics Ltd is engaged in the research, manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and related products. The company specializes in catalyst chemistry and manufactures anthelmintic and veterinary API products. Its product range includes API products, other API products, animal feed ingredients, and reagents for therapeutic use.
44GF Score
Get the complete analysis for NSE:LASA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LASA has been successfully added to your 
